The acceptability of nasal high flow at home in CRD
Research type
Research Study
Full title
The acceptability of nasal high flow at home in chronic respiratory disease: a cross-sectional survey
IRAS ID
317933
Contact name
Swapna Mandal
Contact email
Sponsor organisation
Royal Free London NHS Foundation Trust
Duration of Study in the UK
1 years, 0 months, 1 days
Research summary
Patients with chronic lung diseases often have disabling breathlessness that limits their day to day activities. They are also at increased risk of hospital visits as a consequence.
A new therapy called nasal high flow (NHF) may be of benefit to patients with chronic respiratory disease and disabling breathlessness. Current treatments such as drugs and oxygen therapy can carry risk of drowsiness and confusion when used. Studies over a longer period find that fan therapy is useful in just under half of the patients studied. NHF is a nasal cannula (plastic tube) which sits just under the nostrils and delivers warmed, humidified, high air flow. The cannula are soft and pliable and may offer increased comfort and improved performance compared to plastic cannula that deliver oxygen therapy through the nose. We wish to explore how acceptable NHF may be to a group of patients who have already discussed, trialled or received treatments for their breathlessness in the past and also amongst healthcare professionals (HCPs) who commonly recommend these treatments to patients with chronic lung disease and breathlessness.
Finding new solutions to help patients with chronic lung disease live with, and improve their condition is vital. Nasal high flow may help with self-management of symptoms, physical activity and quality of life.
However, if the treatment is not acceptable to patients or healthcare professionals, clinical trials may not be as effective or recruit sufficient participants, and as a consequence, be underpowered.
We intend to focus on the qualitative aspects by using a cross sectional survey that asks both patients and healthcare professionals about their experiences of treatments used to date, and their acceptability to using nasal high flow in the future. This will ensure future clinical trials encompass this information to plan trials with meaningful results to ensure greatest patient benefit.REC name
South Central - Oxford C Research Ethics Committee
REC reference
22/SC/0420
Date of REC Opinion
3 Nov 2022
REC opinion
Further Information Favourable Opinion